<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589030</url>
  </required_header>
  <id_info>
    <org_study_id>06057</org_study_id>
    <secondary_id>CHNMC-06057</secondary_id>
    <secondary_id>CDR0000579146</secondary_id>
    <secondary_id>NCI-2010-00429</secondary_id>
    <nct_id>NCT00589030</nct_id>
  </id_info>
  <brief_title>Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere (Yttrium-90 Glass Microspheres): A HDE Treatment Use Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near&#xD;
      a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be&#xD;
      effective treatment for liver cancer that cannot be removed by surgery.&#xD;
&#xD;
      PURPOSE: To provide expanded access and study the side effects of yttrium Y 90 glass&#xD;
      microspheres in treating patients with liver cancer that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Provide supervised access to treatment with yttrium Y 90 glass microspheres&#xD;
           (TheraSphere®) to eligible patients with primary cancer to the liver and who are not&#xD;
           surgical resection candidates.&#xD;
&#xD;
        -  Evaluate patient experience and toxicities associated with TheraSphere® treatment.&#xD;
&#xD;
        -  Enter treatment experience into a liver database.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the tumor response rates in patients receiving this treatment.&#xD;
&#xD;
      OUTLINE: This is a humanitarian device exemption use study.&#xD;
&#xD;
      Patients receive yttrium Y 90 glass microspheres (TheraSphere®) via percutaneous hepatic&#xD;
      arterial infusion. Patients may be retreated between 30-90 days after the initial infusion.&#xD;
&#xD;
      After completion of study therapy, patients are followed for 30 days and then annually&#xD;
      thereafter for up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
    <description>The target dose of TheraSphere® is 80-150Gy</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 glass microspheres</intervention_name>
    <description>The target dose of TheraSphere® is 80-150Gy</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of hepatocellular carcinoma&#xD;
&#xD;
          -  Surgical evaluation by a member of the Liver Tumor Program must conclude the patient&#xD;
             is not a candidate for resection or ablation&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status Score 0-2&#xD;
&#xD;
          -  Able to comprehend and provide written informed consent in accordance with&#xD;
             institutional and federal guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absolute granulocyte count =&lt;1,500/ul&#xD;
&#xD;
          -  Platelet count =&lt;75,000/ul&#xD;
&#xD;
          -  Serum creatinine &gt;= 2.0 mg/dl&#xD;
&#xD;
          -  Serum bilirubin&#xD;
&#xD;
               -  &gt;= 2.0 mg/dl for bilateral treatment or lobar treatment&#xD;
&#xD;
               -  &gt;= 3.0 mg/dl for single lesion which could be treated by segmental fusion&#xD;
&#xD;
          -  History of severe allergy or intolerance to any contrast media, narcotics, sedatives,&#xD;
             or atropine&#xD;
&#xD;
          -  Bleeding, diathesis not correctable by usual forms of therapy&#xD;
&#xD;
          -  Severe peripheral vascular disease that would preclude catheterization&#xD;
&#xD;
          -  Portal hypertension with portal venous shunt away from the liver&#xD;
&#xD;
          -  Evidence of potential delivery greater than 16.5 mCi (30 Gy absorbed dose) of&#xD;
             radiation to the lungs on either:&#xD;
&#xD;
               1. first TheraSphere administration; or&#xD;
&#xD;
               2. cumulative delivery of radiation to the lungs &gt; 30 Gy over multiple treatments&#xD;
&#xD;
          -  Evidence of any detectable Tc-99m MMA flow to the stomach or duodenum, after&#xD;
             application of established angiographic techniques to stop such flow&#xD;
&#xD;
          -  Significant extrahepatic disease representing an imminent life-threatening outcome&#xD;
&#xD;
          -  Severe liver dysfunction (Childs' Classification C) or pulmonary insufficiency&#xD;
             (requiring continuous oxygen therapy)&#xD;
&#xD;
          -  Active uncontrolled infection&#xD;
&#xD;
          -  Significant underlying medical or psychiatric illness&#xD;
&#xD;
          -  Pregnant women may not participate&#xD;
&#xD;
          -  Children may not participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Jen Chen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2008</study_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

